Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 Earnings Yield (Joel Greenblatt) % is 5.80% as of Mar. 2026, which is 2% below its 10-year median of 5.92. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Phibro Animal Health ranks better than 74.46% on this metric.
Phibro Animal Health's Enterprise Value for the quarter that ended in Mar. 2026 was $2,954 Mil.
Phibro Animal Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $171 Mil. Phibro Animal Health's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 5.80%.
The historical rank and industry rank for Phibro Animal Health's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PAHC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.49 Med: 5.92 Max: 9.31
Current: 8.15
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Phibro Animal Health was 9.31%. The lowest was 2.49%. And the median was 5.92%.
PAHC's Earnings Yield (Joel Greenblatt) % is ranked better than 74.46% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.115
vs PAHC: 8.15
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Phibro Animal Health's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 9.42%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Phibro Animal Health (NAS:PAHC) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Phibro Animal Health Earnings Yield (Joel Greenblatt) % Related Terms
Phibro Animal Health Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's Earnings Yield (Joel Greenblatt) % falls into.
Phibro Animal Health Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Phibro Animal Healths Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2025 is calculated as
Phibro Animal Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $171 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 5.80% mean?
Phibro Animal Health (PAHC) has a Earnings Yield (Joel Greenblatt) % of 5.80% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 5.92. Over the past decade, Phibro Animal Health's Earnings Yield (Joel Greenblatt) % has ranged from 2.49 to 9.31. According to the industry distribution chart, Phibro Animal Health ranks #258 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 25.5%.
Is Phibro Animal Health's Earnings Yield (Joel Greenblatt) % too high?
Phibro Animal Health's current Earnings Yield (Joel Greenblatt) % of 5.80% is near median its 10-year median of 5.92. Over the past 10 years, this metric has ranged from a low of 2.49 to a high of 9.31. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.12. Phibro Animal Health's value of 5.80% is 86.2% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #258 out of 1010 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Earnings Yield (Joel Greenblatt) % compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #258 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This puts Phibro Animal Health in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.12. Phibro Animal Health's value of 5.80% is 86.2% above this benchmark. Historically, Phibro Animal Health's own Earnings Yield (Joel Greenblatt) % has ranged from 2.49 to 9.31 over the past decade. While the company's 10-year median is 5.92 vs. the industry median of 3.12, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.12, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current Earnings Yield (Joel Greenblatt) % of 5.80% is 86.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current Earnings Yield (Joel Greenblatt) % is 5.80%, which is near median its own 10-year median of 5.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 5.80%, which is near median its 10-year median of 5.92 and 86.2% above the Drug Manufacturers industry median of 3.12. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current Earnings Yield (Joel Greenblatt) % is 5.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
Earnings Yield (Joel Greenblatt) %: 5.80% (near median its 10-year median of 5.92)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 86.2% above the Drug Manufacturers median (#258 of 1010)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
